A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.

Abstract

A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.

Statistics

0204020072008200920102011201220132014201520162017
Citations per Year

64 Citations

Semantic Scholar estimates that this publication has 64 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wang2007ATR, title={A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.}, author={Baolin Wang and Marcela I Henao-Tamayo and Marisa R. Harton and Diane J. Ordway and Crystal A. Shanley and Randall J Basaraba and Ian M. Orme}, journal={Clinical and vaccine immunology : CVI}, year={2007}, volume={14 7}, pages={902-6} }